Drug Watch

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.

Allergan Aesthetics announced the US Food and Drug Administration has approved the hyaluronic acid filler for jawline definition improvement.

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

Approval of a novel oral JAK inhibitor specifically indicated for this challenging condition fills a long unmet need.

An early-stage clinical trial will evaluate an investigational vaccine to prevent Nipah virus infection.

The groundbreaking approval of sirolimus topical gel brings relief to patients with facial angiofibroma related to tuberous sclerosis complex with the first FDA-approved topical treatment.

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.

Verrica is complying with the FDA through 3 Complete Response Letters to achieve the first FDA-approved treatment of molluscum contagiosum.

Complex diseases can be difficult to manage for optimal outcomes. Monitoring programs of therapies can help with that management

In this week’s Pointers with Dr Portela, the 208SkinDoc talks the newest approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata.

Click here to answer this week's poll.

This marks the first FDA approval of a systemic treatment for alopecia areata.

Education, honesty, and communication skills are key for both patient and dermatologist when it comes to creating treatment regimens.

Timber Pharmaceuticals has received an FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis.

Dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals, Inc) has received priority review for its supplemental Biologics License Application by the FDA to treat adult patients with prurigo nodularis.

Dermavant’s new topical treatment for plaque psoriasis in adults was approved by the FDA this morning.

The designation is for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.

A poster from the 2022 American Academy of Dermatology Annual Meeting presented subgroup analyses from the Effisayil 1 study that showed the efficacy of spesolimab was consistent across all prespecified patient populations, including those with or without IL-36RN mutations.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.

The company was asked by the FDA to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.